ANIP FY 2020 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

FY 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$208M+0.9% YoY

Gross Profit

$121M58.2% margin

Operating Income

-$16M-7.7% margin

Net Income

-$23M-10.8% margin

EPS (Diluted)

$-1.88

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

-$53M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$461M

Total Liabilities

$265M

Stockholders' Equity

$196M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$208M	$207M	+0.9%
Gross Profit	$121M	$143M	-15.4%
Operating Income	-$16M	$16M	-198.0%
Net Income	-$23M	$6M	-470.0%